Showing 11-17 of 17 results for "".
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans with rosacea, persi…
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee Act (PDUFA…
- FDA Approves Allergan's Aczone Gel, 7.5% for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-allergans-aczone-gel-75-for-acne-vulgaris/2458681/The FDA approved Allergn’s Aczone (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older. Aczone Gel, 7.5% delivers proven efficacy to treat both inflammatory and non-inflammatory acne, with a new concentration of dapsone in just once-a-day applicat…
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age and older with ABSSSI incl…
- Allergan Expands Neurotoxin Pipeline with Anterios Acquisitionhttps://practicaldermatology.com/news/allergan-expands-neurotoxin-pipelinewith-anterios-acquisition/2458763/Allergan plc has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential develop…
- FDA Approves Updated Label for Allergan's Teflaro for Treatment of ABSSSIhttps://practicaldermatology.com/news/fda-approves-updated-label-for-allergans-teflaro-for-treatment-of-absssi/2458880/The FDA approved Allergan’s supplemental new drug application (sNDA) to update the label for Teflaro® (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The approved label cont…
- Nestlé Skin Health Announces Leadership Teamhttps://practicaldermatology.com/news/nestl-skin-health-announces-leadership-team/2458993/Nestlé Skin Health announced organizational changes at top management level to support the company’s expanded market opportunity and ambition. “Our goal is to grow the number of people the company serves to over a billion within 10 years, by offering skin health solutions that protect, maintain, no…
- Previous
- Next